Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 10180Neoplasms 7807Carcinoma, Non-Small-Cell Lung 5756Prostatic Neoplasms 5024Colorectal Neoplasms 4603Lung Neoplasms 3723Leukemia, Myeloid, Acute 3102Neoplasm Metastasis 3082Multiple Myeloma 3081Pancreatic Neoplasms 2843Melanoma 2651Ovarian Neoplasms 2573Lymphoma 2570Carcinoma, Hepatocellular 2479Stomach Neoplasms 2329Recurrence 2229Head and Neck Neoplasms 2102Precursor Cell Lymphoblastic Leukemia-Lymphoma 2086Lymphoma, Non-Hodgkin 2057Leukemia 2013Brain Neoplasms 1902Glioblastoma 1795Colonic Neoplasms 1790Leukemia, Lymphocytic, Chronic, B-Cell 1771Rectal Neoplasms 1719Uterine Cervical Neoplasms 1693Squamous Cell Carcinoma of Head and Neck 1654Lymphoma, Follicular 1651Lymphoma, Large B-Cell, Diffuse 1597Carcinoma, Renal Cell 1577

Interventions

pembrolizumab 1patritumab deruxtecan 1Platinum Compounds 1Pemetrexed 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Nonsquamous Non-small Cell Lung Cancer × Clear all
NCT05338970 2025-01-31

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Daiichi Sankyo

Phase 3 Active not recruiting
586 enrolled
Thoracic

Nonsquamous Non-small Cell Lung Cancer

NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Taizhou Hanzhong biomedical co. LTD

Phase 2/3 Unknown
700 enrolled
Thoracic

Nonsquamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡